Los Pinos Elisabet De Sells 47,648 Shares of Aura Biosciences (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 47,648 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total value of $241,098.88. Following the transaction, the insider owned 409,815 shares of the company’s stock, valued at $2,073,663.90. This trade represents a 10.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, January 20th, Los Pinos Elisabet De sold 16,928 shares of Aura Biosciences stock. The shares were sold at an average price of $4.86, for a total transaction of $82,270.08.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $5.04 on Thursday. The firm has a market cap of $320.04 million, a price-to-earnings ratio of -2.60 and a beta of 0.46. Aura Biosciences, Inc. has a 52-week low of $4.34 and a 52-week high of $7.80. The firm has a 50 day moving average price of $5.57 and a two-hundred day moving average price of $5.96.

Aura Biosciences News Roundup

Here are the key news stories impacting Aura Biosciences this week:

• Neutral Sentiment: Short-interest report flagged a “large increase” for Feb. 16–17 but shows 0 shares and NaN changes, indicating a likely data/reporting error rather than new short activity. Treat this as informational but not a confirmed market driver. Short interest article
• Negative Sentiment: Cluster of insider sales — Company insiders sold ~104,567 shares combined (approx. $525k–$530k proceeds), reducing individual holdings by ~6–10% each. Notable filings: Los Pinos Elisabet De sold 47,648 shares (~$5.06 avg), Amy Elazzouzi (SVP) sold 8,549 shares (~$5.06), Janet Jill Hopkins sold 20,401 shares (~$5.06), CTO Mark Plavsic sold 15,890 shares (~$5.05), and Conor Kilroy sold 12,079 shares (~$5.05). Large, concurrent insider selling often creates near-term selling pressure and investor concern. SEC filings: Los Pinos filing Elazzouzi filing Hopkins filing Plavsic filing Kilroy filing

Institutional Trading of Aura Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AURA. Dynamic Technology Lab Private Ltd acquired a new stake in Aura Biosciences in the first quarter valued at approximately $137,000. Atria Investments Inc bought a new position in shares of Aura Biosciences in the 2nd quarter worth $190,000. Levin Capital Strategies L.P. lifted its holdings in shares of Aura Biosciences by 9.9% in the 2nd quarter. Levin Capital Strategies L.P. now owns 1,495,560 shares of the company’s stock worth $9,362,000 after purchasing an additional 134,792 shares in the last quarter. Franklin Resources Inc. grew its position in Aura Biosciences by 5.9% in the 2nd quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company’s stock valued at $14,653,000 after purchasing an additional 130,221 shares during the period. Finally, Invesco Ltd. bought a new stake in Aura Biosciences during the 2nd quarter valued at $76,000. 96.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AURA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, December 29th. Evercore started coverage on Aura Biosciences in a research note on Tuesday, November 25th. They set an “outperform” rating for the company. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.50.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.